GPCRs as Partners of LGR5 Cancer Stem Cells: Opportunities and Challenges
- 1Department of Heart, Blood and Kidney Research, Cleveland Clinic Research, Cleveland, OH 44195, USA
- 2Department of Chemistry, Cleveland State University, Cleveland, OH 44115, USA
- 3Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem 91120, Israel
Abstract
Hierarchical organization transpires within a tumor. It is appreciated that cancer stem cells (CSCs) are the cornerstone primary cells of such assemblies, fueled by molecular mechanisms that allow resistance to chemotherapy, vigorous self-renewal capacity, and resistance to immune therapy. Due to their powerful self-renewal capability, CSCs constantly initiate tumor cell proliferation, maintaining the growth state of the tumor. Leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5), a known stem cell niche protein, is a G protein-coupled receptor (GPCR) that is involved in Wnt signaling. It was previously shown that members of protease-activated receptors (PARs) and another affiliate of GPCRs, the G protein-coupled receptor 25 (GPR25), elicit β-catenin stabilization and transcriptional activity. PARs and GPR25 can associate with LGR5 and markedly enhance β-catenin stabilization. The prospect of identifying additional cancer driver GPCRs partners of LGR5, such as the prostaglandin receptors, EP2 and EP4, and the lysophosphatidic acid receptors (LPARs), which have been demonstrated as capable of inducing β-catenin stabilization yet pending experimental association with LGR5, is discussed. The existence of an LGR5-GPCRs-β-catenin hub may potentially overcome tumor plasticity and alleviate drug resistance. It certainly elucidates new opportunities in the fight to eradicate cancer.
Related
- Human Induced Pluripotent Stem Cells in Rare Neurological Disorders: Opportunities and Challenges for Disease Modeling and Drug Discovery.
- Carbon Capture and Utilization Through Microalgae and Carbonic Anhydrases: Opportunities, Challenges and Future Directions
- Beyond petrochemicals: challenges and opportunities in industrial-scale biomanufacturing
- From microbiomes to predictive ecosystems: challenges and opportunities in artificial intelligence-based approaches
- Bilateral exchange in synthetic biology: experiences, challenges, and opportunities for training and research
BibTeX
@article{nag2026gpcrs,
title = {{GPCRs as Partners of LGR5 Cancer Stem Cells: Opportunities and Challenges}},
author = {Jeetendra K. Nag and Ganesh Subedi and Rachel Bar-Shavit},
journal = {Biomolecules},
year = {2026},
month = oct,
doi = {10.3390/biom16101522},
url = {https://www.mdpi.com/2218-273X/16/10/1522},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - GPCRs as Partners of LGR5 Cancer Stem Cells: Opportunities and Challenges
AU - Jeetendra K. Nag
AU - Ganesh Subedi
AU - Rachel Bar-Shavit
PY - 2026
DA - 2026/10/01
JO - Biomolecules
DO - 10.3390/biom16101522
UR - https://www.mdpi.com/2218-273X/16/10/1522
AB - Hierarchical organization transpires within a tumor. It is appreciated that cancer stem cells (CSCs) are the cornerstone primary cells of such assemblies, fueled by molecular mechanisms that allow resistance to chemotherapy, vigorous self-renewal capacity, and resistance to immune therapy. Due to their powerful self-renewal capability, CSCs constantly initiate tumor cell proliferation, maintaining the growth state of the tumor. Leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5), a known stem cell niche protein, is a G protein-coupled receptor (GPCR) that is involved in Wnt signaling. It was previously shown that members of protease-activated receptors (PARs) and another affiliate of GPCRs, the G protein-coupled receptor 25 (GPR25), elicit β-catenin stabilization and transcriptional activity. PARs and GPR25 can associate with LGR5 and markedly enhance β-catenin stabilization. The prospect of identifying additional cancer driver GPCRs partners of LGR5, such as the prostaglandin receptors, EP2 and EP4, and the lysophosphatidic acid receptors (LPARs), which have been demonstrated as capable of inducing β-catenin stabilization yet pending experimental association with LGR5, is discussed. The existence of an LGR5-GPCRs-β-catenin hub may potentially overcome tumor plasticity and alleviate drug resistance. It certainly elucidates new opportunities in the fight to eradicate cancer.
SN - 2218-273X
ER -